Atopic Dermatitis News

• Novel JAK Inhibitor Improves QOL in Chronic Hand Eczema Treatment with delgocitinib cream leads to improvement in health-related quality of life in patients with moderate to severe chronic hand eczema, according to a phase 2b trial.
  Medscape News UK, April 10, 2025
• New Scoring System May Streamline Food Allergy Diagnosis The NAPFA score may predict which children have a food allergy, even without allergy test results.
  Medscape Medical News, April 09, 2025
• Infections Higher With JAK Inhibitors in Eczema Study A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.
  Medscape Medical News, April 09, 2025
• Early-Onset Atopic Dermatitis Raises Uveitis Risk in Kids A cohort study finds children with early-onset atopic dermatitis to be at increased risk for uveitis, highlighting a need for ophthalmologic monitoring in youth.
  Medscape Medical News, April 04, 2025
• Risk for Peanut-Triggered FPIES Low With Early Introduction Infants of parents with atopic disease, introduced to peanuts between ages 4 and 11 months, have a low prevalence of peanut-triggered food protein–induced enterocolitis syndrome, new research shows.
  Medscape Medical News, March 25, 2025
• AAD 2025 Upadacitinib Dosing Increases or Decreases Found Safe in AD A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient response without serious adverse effects.
  Medscape Medical News, March 20, 2025
• Real-World Study Reveals Early Success of Upadacitinib in AD Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.
  Medscape News UK, March 20, 2025
• AAD 2025 Novel Therapy Shown Effective for Atopic Dermatitis A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat immune-mediated diseases.
  Medscape Medical News, March 18, 2025
• Avocados in Pregnancy Linked to Lower Infant Allergy Risk One-year-olds may have lower odds of having food allergies if their mothers ate avocados during pregnancy, new research shows.
  Medscape Medical News, March 13, 2025
• AAD 2025 Delgocitinib Cream Produces Robust Response to Eczema Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped treatment stayed clear or nearly clear for 8 weeks.
  Medscape Medical News, March 09, 2025
• Poor Air Quality Linked to AD Risk in Offspring Prenatal exposure to fine particulate matter (PM2.5) at levels above 65 µg/m³ was associated with a sharp rise in atopic dermatitis (AD) in a birth cohort study.
  Medscape Medical News, March 09, 2025
• Can Smokers Safely Use Upadacitinib for Atopic Dermatitis? Upadacitinib is potentially safe and effective for patients with moderate to severe atopic dermatitis, irrespective of smoking status.
  Medscape News UK, March 06, 2025
• Dermatomyositis Misdiagnosis Common, Affects Outcomes A retrospective study highlights the high misdiagnosis rates of dermatomyositis, particularly its amyopathic subtype, and the associated increase in hospitalizations and worse lung function.
  Medscape Medical News, February 27, 2025
• FDA Reviewing Roflumilast for Atopic Dermatitis in Toddlers Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years.
  Medscape Medical News, February 27, 2025
• Does COVID-19 Worsen Skin Disease Outcomes? COVID-19 has little impact on patients with dermatological immune-mediated inflammatory diseases, with effective seroconversion after vaccination and few patients showing increased disease activity.
  Medscape News UK, February 20, 2025
• Nemolizumab Approved for AD, Prurigo Nodularis in Europe The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.
  Medscape Medical News, February 19, 2025
• MHRA Approves Nemolizumab for Eczema and Prurigo Nodularis The MHRA has granted marketing authorisation to nemolizumab to treat prurigo nodularis in adults and atopic dermatitis in people aged 12 and over.
  Medscape News UK, February 18, 2025
• Pause Immunosuppressants Prior to Patch Testing If Possible Testing patients on immunosuppressant medications can yield false negatives.
  Medscape Medical News, February 12, 2025
• AI Hand Sensor Reduces Night Scratching in Atopic Dermatitis A small cohort study found that a wearable hand sensor that uses artificial intelligence reduced subconscious nighttime scratching in people with mild atopic dermatitis.
  Medscape Medical News, February 05, 2025
• Stress Linked to Atopic Dermatitis Activity in Children Experiencing stressful life events in childhood was associated with an increased risk for active and severe atopic dermatitis, in a large cohort study.
  Medscape Medical News, February 03, 2025